HGF and Fuchs' endothelial dystrophy: Future in vivo studies are warranted to further explore the clinical applicability of HGF in treating corneal endothelial dysfunction, particularly in conditions like Fuchs’ endothelial dystrophy (FED), where donor tissue availability remains a critical challenge.